New drug combo aims to control resistant blood cancers
NCT ID NCT06466122
Summary
This study is testing whether combining two oral medications, pirtobrutinib and venetoclax, can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients whose cancer has continued to grow despite treatment with standard BTK inhibitor drugs. The main goal is to see if this combination can make the cancer undetectable by very sensitive tests. The trial will enroll about 30 adults who are currently taking a BTK inhibitor but show signs their disease is worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.